Partnership with MD PHD Wellness Establishes a Long-Term Product Pipeline; Flagship Formulation to Be Marketed Under Synbio’s Healing Force™ Brand

NEW YORK, NY – TheNewswire - Sept. 8, 2026 – Synbio International, Inc. (OTC: SYIN) today announced it has entered into a Strategic Licensing, Manufacturing, Supply and Revenue Sharing Agreement with MD PHD Wellness, Inc., securing the exclusive rights to commercialize MD PHD Wellness’ proprietary nutraceutical formulations throughout the United States and Canada.

The agreement covers MD PHD Wellness’ flagship anti-anxiety nutraceutical formulation, to be marketed under Synbio’s Healing Force™ brand, and establishes a framework for the parties to evaluate and commercialize additional proprietary wellness products over time. Importantly, it provides Synbio with immediate access to proprietary nutraceutical products without the time and cost burden of developing formulations from scratch, significantly accelerating the Company’s path to revenue generation.

Under the agreement, MD PHD Wellness will oversee product development, manufacturing, quality assurance, and supply chain management, while Synbio will be responsible for branding, marketing, sales, and distribution. Following recovery of approved manufacturing and commercialization costs, profits generated from product sales will be shared between the parties.

“This agreement represents a transformational milestone for Synbio,” said Claudio Solitario, Chief Executive Officer of Synbio International. “Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD’s product development and manufacturing expertise with Synbio’s commercialization capabilities. It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time, allowing management to focus on creating the greatest shareholder value — building brands, generating sales and expanding market presence.”

Solitario continued, “We believe this partnership creates an efficient and scalable business model. As the global nutraceutical market continues its rapid expansion, Synbio is now positioned to participate through a growing portfolio of scientifically developed products while simultaneously advancing our longer-term AI-driven healthcare technologies.”

Scientific Leadership

MD PHD Wellness was founded by Dr. Robert Lawrence, a physician, scientist and inventor who holds two Ph.D. degrees, in Nuclear Physics and Biomedical Engineering, and whose career spans medicine, biomedical engineering, microbiology, pharmacology and nutraceutical development. He has developed numerous nutraceutical products, and his research includes innovations in cellular regeneration, natural product delivery systems, medical technologies and pharmaceutical applications.

Co-founder Dr. David Anderson is an experienced physician, researcher and scientific consultant who played a key role in developing the proprietary formulations licensed to Synbio, with extensive expertise in nutraceuticals, medical technologies and scientific claims substantiation. He served as a Research Physician and Senior Research Scientist at a prominent New York-based university, where he participated in the evaluation and scientific validation of therapeutics, nutraceuticals and emerging healthcare technologies. His work has included collaborations with leading academic institutions, government agencies and commercial organizations, and he has been recognized in Marquis Who’s Who for his professional achievements.

Building a Diversified Healthcare Company

The agreement advances Synbio’s broader strategy of building a diversified healthcare company that pairs near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies — a dual-track approach the Company believes provides multiple avenues for growth while establishing recurring commercial revenue that can support continued investment in innovation.

About Synbio International Inc.

Synbio International Inc (SYIN) is a company focused on clinically validating an AI-driven software that will screen for mental health conditions using facial analysis. Through strategic partnerships and research collaborations, Synbio aims to help develop and validate science-based solutions that improve the quality of life and empower healthcare providers. To generate early revenue while its software advances through validation, Synbio plans to launch a line of nutraceutical products sold directly to consumers online in 2026.

For inquiries, please contact:
Synbio International Inc.
info@synbiointl.com
(646) 359-4854
www.synbiointl.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements in this press include, among others, statements about our licensing agreement with MD PHD Wellness, Inc., our planned entry into the nutraceutical market, the timing and amount of any revenue we may generate, and the development of our AI-driven healthcare technologies. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans, and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our limited operating history; our dependence on third parties for many aspects of our business; general market and economic conditions; technical factors; the availability of outside capital; our receipt of revenues; legislative developments; changes in our expenditures and other uses of cash; our ability to find, recruit and retain personnel in sufficient numbers to support our growth; our ability to manage growth; and general market, economic and business conditions. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.